Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps evolving and
mutating into newer variants over time, which gain higher transmissibility, disease severity …

The ongoing COVID‐19 pandemic caused by SARS‐CoV‐2 is associated with high
morbidity and mortality. This zoonotic virus has emerged in Wuhan of China in December …

Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …

ABSTRACT Introduction On 31 July 2023, the United States Department of Health and
Human Services announced the formation of the Office of Long COVID Research and …

COVID-19 caused by SARS-CoV-2 has posed a significant threat to global public health
since its outbreak in late 2019. Although there are a few drugs approved for clinical …

A compound that could inhibit multiple targets associated with SARS-CoV-2 infection would
prove to be a drug of choice against the virus. Human receptor-ACE2, receptor binding …

Background Real-world evidence on the effectiveness of oral antivirals in mild-to-moderate
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …

Introduction First-generation therapeutics have improved clinical outcomes in patients
infected with SARS-CoV-2. However, viral evolution has produced variants and subvariants …

Evidence in SARS-CoV-2 patients have identified that viral infection is accompanied by the
expression of inflammatory mediators by both immune and stromal cells within the …

Abstract On December 22, 2021, the United States Food and Drug Administration approved
the first main protease inhibitor, ie, oral antiviral nirmatrelvir (PF-07321332)/ritonavir …